Home > Ardea Biosciences Salary

Ardea Biosciences Salary

  • 20
  • 40
  • 82
Ardea Biosciences average salary is $95,834, median salary is $87,500 with a salary range from $80,000 to $120,000.
Ardea Biosciences salaries are collected from government agencies and companies. Each salary is associated with a real job position. Ardea Biosciences salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
80,000
Average
95,834
Median
87,500
High
120,000
Total 3 Ardea Biosciences Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Director Of Operations 120,000-120,000 New York, NY, 10001 2016 Ardea Biosciences Director Of Operations Salaries (1)
Ardea Biosciences New York, NY Salaries
General Manager 87,500-87,500 New York, NY, 10001 2014 Ardea Biosciences General Manager Salaries (2)
Ardea Biosciences New York, NY Salaries
General Manager 80,000-80,000 New York, NY, 10001 2012 Ardea Biosciences General Manager Salaries (2)
Ardea Biosciences New York, NY Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Ardea Biosciences salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Ardea Biosciences Jobs
See more Ardea Biosciences Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Patents information
951

All Patents

252

Grant Patents

572

Patents Pending

100

Patents Families

More Recent
Ardea Biosciences... Information
  • Ardea Biosciences, Inc.
  • Industry: BioTech/Drugs
  • City: San Diego, CA
  • IntraBiotics Pharmaceuticals, Inc., founded in 1994, is a biopharmaceutical company engaged in the development of novel antibacterial and antifungal for the treatment and prevention of serious infectiousdiseases, including those caused by multi-drug resistant pathogens. TheCompany plans to continue to build product line extensions through newformulations and new indications for its products that have progressed beyondPhase I.